[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts

Mette Munk Jensen, Kamille Dumong Erichsen, Camilla Bardram Johnbeck, Fredrik Björkling, Jacob Madsen, Michael Bzorek, Peter Buhl Jensen, Liselotte Højgaard, Maxwell Sehested, Andreas Kjær

23 Citationer (Scopus)

Abstract

APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.
OriginalsprogEngelsk
TidsskriftP L o S One
Vol/bind8
Udgave nummer1
Sider (fra-til)e53410
ISSN1932-6203
DOI
StatusUdgivet - 2013

Fingeraftryk

Dyk ned i forskningsemnerne om '[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts'. Sammen danner de et unikt fingeraftryk.

Citationsformater